PTGX catalyst calendar

Protagonist Therapeutics, Inc

Upcoming catalysts
1
Cash runway
48 months
Cash & investments
$783M
Phase 3 programs
2

Protagonist Therapeutics, Inc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There is 1 upcoming event on record.

Cash runway is approximately 48 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 11 concluded trials, 91% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 5, 2026 est. Next quarterly earnings (projected) Earnings —

Track PTGX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open PTGX in the tracker

Recent history

DateEventTypePhase
August 5, 2026 Quarterly results filed (8-K) Earnings —
July 29, 2026 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects. Trial Milestone Phase 1
June 18, 2026 8-K filed: Leadership change Corporate —
May 5, 2026 Quarterly results filed (8-K) Earnings —
April 1, 2026 Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera Trial Milestone Phase 3
February 25, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 8-K filed: Reg FD disclosure Filing —
November 6, 2025 Quarterly results filed (8-K) Earnings —
August 6, 2025 Quarterly results filed (8-K) Earnings —
May 6, 2025 Quarterly results filed (8-K) Earnings —
February 21, 2025 A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera Trial Milestone Phase 3
March 15, 2023 PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit Trial Milestone Phase 2
February 16, 2023 PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC) Trial Milestone Phase 2
February 14, 2023 Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) Trial Milestone Phase 2
December 17, 2021 Pharmacokinetics of PN-232 in Healthy Volunteers Trial Milestone Phase 1
October 6, 2021 PTG-300 in Subjects With Hereditary Hemochromatosis Trial Milestone Phase 2
September 19, 2021 Pharmacokinetics of PN-235 in Healthy Volunteers Trial Milestone Phase 1
January 12, 2021 Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers Trial Milestone Phase 1
July 31, 2020 Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia Trial Milestone Phase 2
July 31, 2020 Safety Study for Beta Thalassemia Subjects on PTG-300 Trial Milestone Phase 2
March 26, 2018 Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.